Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$1.29B+5841.29%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ugur Sahin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,807
- Beta
- 1.33
- Country
- DE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.45
Financials
Revenue
$1.29B+5841.3%Net Income
$184.50MEBITDA
$562.60MFree Cash Flow
$-163.40MEPS (diluted)
$0.73Shares Outstanding (diluted)
253.00M+30.7%Operating Expenses
$926.60MCash & Debt
$10.20BReturn of Capital
$274.30MRevenue by Segment (annual)
$261.60MDividend per Share
$2.11Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.76B | $-1.09B | $-4.51 |
| 2024 | $2.75B | $-665.30M | $-2.77 |
| 2023 | $3.82B | $930.30M | $3.87 |
| 2022 | $17.31B | $9.43B | $38.08 |
| 2021 | $18.98B | $10.29B | $43.87 |
| 2020 | $482.30M | $15.20M | $0.06 |
| 2019 | $108.60M | $-179.10M | $-0.85 |
| 2018 | $127.58M | $-48.02M | $-0.21 |
| 2017 | $61.60M | $-85.65M | $-0.38 |
Valuation
BNTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-86.86%Social Signal Score
Mentions (25)
- Newsseekingalpha.com·18d ago·Negative
…tistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.
View source ↗ - Newsseekingalpha.com·19d ago·Neutral
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Partic…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
BioNTech Q3 Earnings Call Highlights BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulato
View source ↗ - Newsreuters.com·31d ago·Negative
BioNTech, Gilead to test drug combination in advanced breast cancer trial BioNTech, Gilead to test drug combination in advanced breast cancer trial
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
…Tech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provi…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company's tumor focus areas, including lung and breast cancer, at the European Society for Medical Oncology (“ESMO”) 2026 Congress held in Madrid, Spain, from October 23–27, 2026.
View source ↗ - Newsfool.com·35d ago·Positive
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? BioNTech needs new products to kickstart sales and earnings growth. But two of the company's candidates have experienced setbacks recently.
View source ↗ - Newsprnewswire.com·39d ago·Negative
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements about its mRNA oncology programs gave shareholders an accurate picture.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or “tenu-ra”).
View source ↗ - Newszacks.com·41d ago·Positive
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
View source ↗ - Newsdefenseworld.net·42d ago·Negative
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the company's stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares
View source ↗ - Newsdefenseworld.net·42d ago·Negative
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 27,000 shares of the company's stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $92.31, for a total value of $2,492,370.00. Following the completion of the transaction, the chief executive officer owned
View source ↗ - Newsfool.com·45d ago·Neutral
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? BioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026. Pumitamig is being tested across lung, breast, gastric, and kidney cancers, giving the drug multiple paths to commercial success.
View source ↗ - Newsreuters.com·55d ago·Negative
BioNTech to shutter sites in Germany, Singapore as no buyers emerge German COVID‑19 vaccine maker BioNTech said on Monday it would close sites in Germany and Singapore because it failed to find buyers after pivoting away from pandemic-era manufacturing.
View source ↗ - Newsfool.com·61d ago·Negative
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback.
View source ↗ - Newsfool.com·65d ago·Neutral
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer.
View source ↗ - Newsreuters.com·69d ago·Negative
BioNTech says lung cancer drug candidate prolonged lives in trial BioNTech said on Monday that a late-stage trial showed its drug candidate gotistobart led to a clinically meaningful overall survival benefit in a certain form of lung cancer compared with standard treatment.
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
…of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease …
View source ↗ - Newsfool.com·81d ago·Negative
Is BioNTech Stock a No-Brainer Buy on the Dip? BioNTech has not performed well in recent years, as its COVID-19 portfolio has struggled. However, the company's mRNA platform is looking increasingly valuable.
View source ↗ - Newszacks.com·83d ago·Neutral
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
View source ↗ - Newsseekingalpha.com·86d ago·Neutral
…On COMIRNATY Variant Expansion And More BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand headwinds, reflected in lowered 2026 guidance…
View source ↗ - Newsbenzinga.com·86d ago·Neutral
BioNTech Stock Dips After BNT122-01 Trial Termination BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate its Phase 2 clinical trial of autogene cevumeran in resected colorectal cancer. Here's what you should know.
View source ↗ - Newsreuters.com·86d ago·Neutral
BioNTech to terminate mid-stage trial of mRNA cancer vaccine BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, sending the German firm's U.S.-listed shares down nearly 9%.
View source ↗ - Newsbenzinga.com·95d ago·Neutral
Why Is BioNTech Stock Surging on Wednesday? BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to Merck & Co Inc. (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) topline data from individualized cancer therapy for advanced skin cancer.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $-1.87 per share
Typical surprise +9.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.83 vs $0.76beat
- Tue, Aug 4$-3.70 vs $-2.40miss
- Tue, May 5$-2.43 vs $-2.54beat
- Tue, Mar 10$-1.44 vs $-0.22miss
- Mon, Nov 3$-0.14 vs $-1.12beat
- Mon, Aug 4$-1.82 vs $-2.69beat
Estimates and results for BNTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BNTX officers and directors.
- Bought
- —
- Sold
- $89.8m
0 trades
27 trades
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
- Sahin Ugursold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (36d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (30d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Sep 11, 2024 (12d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 15, 2024 (30d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 7, 2024 (24d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (33d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (32d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (19d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
